Literature DB >> 23675659

Current and future therapies for hepatitis C virus infection.

T Jake Liang1, Marc G Ghany.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23675659      PMCID： PMC3893124          DOI： 10.1056/NEJMra1213651

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  67 in total

1.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Authors: 
Journal:  J Hepatol       Date:  2011-03-01       Impact factor: 25.083

2.  Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.

Authors:  Sandra De Meyer; Inge Dierynck; Anne Ghys; Maria Beumont; Bjorn Daems; Ben Van Baelen; James C Sullivan; Douglas J Bartels; Tara L Kieffer; Stefan Zeuzem; Gaston Picchio
Journal:  Hepatology       Date:  2012-12       Impact factor: 17.425

3.  Potent inhibitors of hepatitis C core dimerization as new leads for anti-hepatitis C agents.

Authors:  Feng Ni; Smitha Kota; Virginia Takahashi; A Donny Strosberg; John K Snyder
Journal:  Bioorg Med Chem Lett       Date:  2011-04-15       Impact factor: 2.823

4.  The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.

Authors:  Robert Flisiak; Saya V Feinman; Maciej Jablkowski; Andrzej Horban; Wieslaw Kryczka; Małgorzata Pawlowska; Jenny E Heathcote; Giuseppe Mazzella; Carmen Vandelli; Valérie Nicolas-Métral; Pierre Grosgurin; Jorge S Liz; Pietro Scalfaro; Hervé Porchet; Raf Crabbé
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

5.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

Review 6.  Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy.

Authors:  Julie R Jonsson; David M Purdie; Andrew D Clouston; Elizabeth E Powell
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

7.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

8.  An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Authors:  Marc G Ghany; David R Nelson; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2011-09-26       Impact factor: 17.425

9.  The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.

Authors:  Sam Hopkins; Michael Bobardt; Udayan Chatterji; Jose A Garcia-Rivera; Precious Lim; Philippe A Gallay
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

10.  Exploratory study of oral combination antiviral therapy for hepatitis C.

Authors:  Fred Poordad; Eric Lawitz; Kris V Kowdley; Daniel E Cohen; Thomas Podsadecki; Sara Siggelkow; Michele Heckaman; Lois Larsen; Rajeev Menon; Gennadiy Koev; Rakesh Tripathi; Tami Pilot-Matias; Barry Bernstein
Journal:  N Engl J Med       Date:  2013-01-03       Impact factor: 91.245
View more
  170 in total

1.  Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline.

Authors:  Daniel John Smyth; Duncan Webster; Lisa Barrett; Mark MacMillan; Lisa McKnight; Frank Schweiger
Journal:  Can J Gastroenterol Hepatol       Date:  2014-11

2.  Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle.

Authors:  Shanshan He; Kelin Li; Billy Lin; Zongyi Hu; Jingbo Xiao; Xin Hu; Amy Q Wang; Xin Xu; Marc Ferrer; Noel Southall; Wei Zheng; Jeffrey Aubé; Frank J Schoenen; Juan J Marugan; T Jake Liang; Kevin J Frankowski
Journal:  J Med Chem       Date:  2017-07-13       Impact factor: 7.446

3.  Membranoproliferative glomerulonephritis: the times they are a-changin'.

Authors:  Jan Willem Cohen Tervaert
Journal:  Clin Exp Nephrol       Date:  2013-08-28       Impact factor: 2.801

4.  Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.

Authors:  N Saraiya; A C Yopp; N E Rich; M Odewole; N D Parikh; A G Singal
Journal:  Aliment Pharmacol Ther       Date:  2018-05-30       Impact factor: 8.171

5.  Identification of Cholesterol 25-Hydroxylase as a Novel Host Restriction Factor and a Part of the Primary Innate Immune Responses against Hepatitis C Virus Infection.

Authors:  Yu Xiang; Jing-Jie Tang; Wanyin Tao; Xuezhi Cao; Bao-Liang Song; Jin Zhong
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

6.  Burden of Hepatitis C Virus Infection Among Older Adults in Long-Term Care Settings: a Systematic Review of the Literature and Meta-Analysis.

Authors:  Kimberly J Alvarez; Arlene Smaldone; Elaine L Larson
Journal:  Curr Infect Dis Rep       Date:  2016-03       Impact factor: 3.725

Review 7.  Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease.

Authors:  Mahrukh Akbar Shaheen; Muhammad Idrees
Journal:  World J Hepatol       Date:  2015-03-27

Review 8.  Enhancing our understanding of current therapies for hepatitis C virus (HCV).

Authors:  Neliswa A Gogela; Ming V Lin; Jessica L Wisocky; Raymond T Chung
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

9.  Infection of Hepatocytes With HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Up-regulating SMAD6 and SMAD7.

Authors:  Fang Zhang; Catherine Sodroski; Helen Cha; Qisheng Li; T Jake Liang
Journal:  Gastroenterology       Date:  2016-09-30       Impact factor: 22.682

Review 10.  Therapeutic Potential of Spirooxindoles as Antiviral Agents.

Authors:  Na Ye; Haiying Chen; Eric A Wold; Pei-Yong Shi; Jia Zhou
Journal:  ACS Infect Dis       Date:  2016-05-05       Impact factor: 5.084
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.